EMEA-002387-PIP02-21
Key facts
Invented name |
Nexpovio
|
Active substance |
Selinexor
|
Therapeutic area |
Oncology
|
Decision number |
P/0364/2021
|
PIP number |
EMEA-002387-PIP02-21
|
Pharmaceutical form(s) |
Tablet
|
Condition(s) / indication(s) |
Treatment of endometrial carcinoma
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Karyopharm Europe GmbH
E-mail: cnippgen@karyopharm.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|